de-escalate patients who are unlikely to benefit from extended endocrine therapy
Published 5 months ago • 17 plays • Length 2:24Download video MP4
Download video MP3
Similar videos
-
1:36
de-escalating clinically high risk patients who are not likely to benefit from eet
-
4:18
managing patients with high risk of recurrence who are unlikely to benefit from eet
-
12:16
de-escalation and escalation strategies for her2 breast cancer
-
1:00:46
partnering to provide personalized care: patient selection for extended endocrine therapy
-
32:12
education session: "escalating and de-escalation - titrating the right regimen in early stage"
-
1:00
therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancer
-
22:14
adjuvant endocrine therapy in postmenopausal women: risk stratification, type & duration
-
1:17
future advances in dcis: de-escalation of hormonal therapy
-
1:04:51
international virtual round table| debate: dr. matthew ellis & dr. alastair thompson
-
44:53
overcoming drug resistance to cancer therapies
-
0:54
treatment de-escalation in premenopausal patients with hr /her2- breast cancer and micro-metastasis
-
58:10
breast cancer management in north carolina: updates for 2020 - e. ray - 20200722
-
2:01
the fundamentals of de-escalation in oncology
-
1:38
de-escalating surgery for patients with early-stage breast cancer
-
46:57
winship grand rounds march 1, 2017: lisa carey, md
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
1:11:49
2021 best of breast | case 6 side effects